Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study
Open accessThe DOI matches its Crossref record.
Abstract
ZEUS study was an open-label, 12-month, multicenter study in which 300 de novo kidney transplant recipients were randomized to continue receiving cyclosporine (CsA) or convert to everolimus at 4.5 months posttransplant. Five-year follow-up data were available for 245/269 patients (91.1%) who completed the core 12-month study (123 everolimus, 109 CsA). At 5 years, adjusted estimated GFR was 66.2 mL/min/1.73 m(2) with everolimus versus 60.9 mL/min/1.73 m(2) with CsA; the mean difference was 5.3 mL/min/1.73 m(2) in favor of everolimus (95% CI 2.4, 8.3; p < 0.001 [intent-to-treat population]). In a post hoc analysis of patients remaining on study drug at 5 years (everolimus 77, CsA 86), mean difference was 8.2 mL/min/1.73 m(2) (95% CI 4.3, 12.1; p < 0.001) in favor of everolimus. The cumulative incidence of biopsy-proven acute rejection postrandomization was 13.6% with everolimus versus 7.5% with CsA (p = 0.095), largely accounted for by grade I rejection (16/21 patients and 7/11 patients, respectively). Postrandomization, graft loss, mortality, serious adverse events and neoplasms were similar in both arms. In conclusion, conversion of kidney transplant patients to everolimus at 4.5 months posttransplant is associated with a significant improvement in renal function that is maintained to at least 5 years. The increase in early mild acute rejection did not affect long-term graft function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Baker, R. J., Mark, P. B., Patel, R. K., Stevens, K. K., & Palmer, N. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0553-2 · Cited by 211
“While both studies demonstrated shortterm improvements in renal function, there were no significant improvements in long term graft or patient outcomes [26, 27, 224].”
ResultRoles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Viana, S. D., Reis, F., & Alves, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3693625 · Cited by 48
“The followup of these patients at five years confirmed that in the first year posttransplant grafts presented better function, but also a higher incidence of acute rejection [76].”
Background
Metadata
- Authors
- Budde, K., Lehner, F., Sommerer, C., Reinke, P., Arns, W., Eisenberger, U., Wüthrich, R. P., Mühlfeld, A., Heller, K., Porstner, M., Veit, J., Paulus, E.-M., & Witzke, O.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 15
- Issue
- 1
- Pages
- 119-128
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W1597697188
- Cited by
- 130
- References
- 0
- FWCI
- 19.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study. https://app.cochat.ai/papers/10.1111/ajt.12952
- The paper
- Budde, K., Lehner, F., Sommerer, C., Reinke, P., Arns, W., Eisenberger, U., Wüthrich, R. P., Mühlfeld, A., Heller, K., Porstner, M., Veit, J., Paulus, E.-M., & Witzke, O. (2015). Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study. American Journal of Transplantation. https://doi.org/10.1111/ajt.12952
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.